Abstract
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) belong to the same spectrum (‘epidermal necrolysis’) of rare, potentially life-threatening conditions usually caused by drugs. The causative drug should be quickly identified and discontinued. At the acute phase, the cornerstone of the management of SJS/TEN is supportive care in a center of reference (dermatology, burn or intensive care unit): warm environment, fluid replacement, nutritional support, analgesia, organ support, surveillance for infection, mucous membrane (especially ocular) management, and appropriate dressings. Respiratory failure can occur, requiring mechanical ventilation. The efficacy of immunomodulatory agents (including systemic steroids, ciclosporin, intravenous immunoglobulins, anti-tumor necrosis factor such as etanercept) at the acute phase of the disease remains of debate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
